The Medical Services Advisory Committee (MSAC) has rejected an application to fund the potentially life saving CAR T-cell therapy, tisagenlecleucel, for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The ruling is a blow for the costly treatment, which was anticipated to be in more widespread use after it gained Therapeutic Goods Administration ...
MSAC rejection of CAR T-cell therapy for DLBCL disappointing: Prof Miles Prince
By Sunalie Silva
5 Nov 2019